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Abstract 
Rodwan, Naima. M.S., Department of Pharmacology and Toxicology, Wright State University, 2012. 
Light-Limited Access to Fructose Alters Metabolic Function and Adipose Tissue 
Catecholaminergic Activity in Mice 
 
Consumption of high levels of fructose produces glucose intolerance, sympathetic nervous 
system activation, and renal dysfunction. A diet high in fructose may play a role in the 
worldwide epidemic of obesity and diabetes. The aim of this study was to test the hypothesis 
that time (light/dark) limited access to fructose influences body fat, metabolic function, and 
adipose tissue catecholaminergic activity in mice. Male C57BL/6 mice were given standard 
chow and assigned to one of three groups: Control (n=10, water 24h); FL (n=11, 10% fructose 
solution during 12h light period); and FD (n=10, 10% fructose solution during 12h dark 
period). Metabolic parameters measured were body fat (BF, Echo-MRI), adipocyte cell size, and 
glucose tolerance as well as plasma glucose, adiponectin, insulin, leptin, triglycerides, and 
cholesterol. Catecholamine levels were measured directly in white adipose tissue (WAT) using 
high performance liquid chromatography (HPLC) with electrochemical detection. 
Immunochemistry was used for examining tyrosine hydroxylase (TH) staining in WAT 
and brainstem. Mice given fructose during the light phase (inactive period for mice) showed 
evidence for a diabetic like symptoms with prominent changes in adipose tissue fat. Results 
showed:  1) enhanced increase in BF and increased size of adipocytes in FL; 2) increased plasma 
insulin and leptin in FL without changes in glucose or glucose tolerance; 3) no change in 
cholesterol or triglycerides; 4) measurable amounts of norepinephrine (NE), epinephrine (EPI) in 
WAT without difference among groups; 5) enhanced staining for TH in WAT and brainstem 
locus coeruleus. The changes in adiposity occurred even though caloric intake was not different 
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among groups.  In conclusion, results document that restriction of fructose access to the light 
period produced pathological effects on metabolic function along with catecholaminergic 
activation in WAT and brainstem. These data may have clinical implications since the timing of 
intake may be important in the control of adiposity and the development of metabolic syndrome. 
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1. INTRODUCTION 
1.1 Adipose tissue overview 
 
 
 
 
 
 
 
 
Figure 1: H & E staining in WAT from an obese mouse. 
 Fat cells are approximately twice as large as controls. 
 
White adipose tissue (WAT) forms the largest fat depot in the body, localized primarily in the 
abdomen and the subcutaneous layer. The fat is stored in adipocytes which form a mesh-like 
cellular network (Figure 1). The cells act as storage vessels for triglyceride (TG) which is 
metabolized to release free fatty acids (FFAs) into the circulation.  FFAs in turn provide energy 
for bodily functions.  WAT also contains preadipocytes, fibroblasts, mast cells, mesenchymal 
cells, endothelial cells, and stromovascular cells (Frayn, Karpe, Fielding, Macdonald, & 
Coppack, 2003).  WAT is considered to be an endocrine organ because it produces the metabolic 
hormones, leptin, adiponectin, and resistin as well as the immunological modulators, IL-6 and 
TNF-α. 
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1.2. Leptin 
Leptin is a 167-amino acid peptide (Brennan & Mantzoros, 2006; Zhang et al., 1997) produced 
almost exclusively in adipose tissue (Margetic, Gazzola, Pegg, & Hill, 2002). Its secretion is  
influenced by fat mass and changes in energy status (Considine et al., 1996). A reduction of 
leptin either in humans or rodents leads to increased body weight (BW) and body fat (BF). 
Leptin is particularly important in the obesity syndrome because it regulates food intake and 
energy expenditure (Zhang et al., 1994). Leptin binds to leptin receptors (ObRbs) located 
throughout the central nervous system (CNS) and peripheral tissues (Fei et al., 1997). The ObRb 
receptor is highly expressed in the hypothalamus, which is involved in energy homeostasis 
(Elmquist, Bjorbaek, Ahima, Flier, & Saper, 1998; Fei et al., 1997). After release from 
adipocytes, leptin is transported though the blood-brain barrier into the CNS, where it causes 
hunger inhibition and a sensation of satiety. Insulin and leptin, act together as peripheral signals 
to the CNS, regulating feeding behavior and metabolic homeostasis (Niswender & Schwartz, 
2003). The nocturnal rise in leptin secretion is entrained to mealtime probably responding to the 
cumulative hyperinsulinemia which stimulates leptin secretion from adipose tissue (Sinha & 
Caro, 1998). Change or deletion in leptin receptors has the opposite effects, obesity and diabetes.  
An example of a pathological genetic model is the db/db mouse which has a mutation of the Ob 
receptor (White & Tartaglia, 1996). A mutation in a human gene in similar manner produced 
obesity and glucose intolerance, (Licinio et al., 2004)  
1.3. Leptin and insulin 
Leptin has peripheral effects on insulin secretion and insulin action which leads to changes in 
metabolism of adipocytes, skeletal muscle, and other tissues. Leptin is considered to be an 
important regulator of peripheral glucose homeostasis. Like leptin, insulin also has receptors in 
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the hypothalamus with secretion proportional to fat stores (Baskin, Wilcox, Figlewicz, & Dorsa, 
1988). Experimental studies have shown that prolonged intravenous leptin infusion increases 
glucose use and increases tissue sensitivity to insulin. Insulin plays an important role in the 
regulation of leptin secretion and vice versa for leptin and insulin secretion. It is thought that 
insulin increases leptin production by adipose tissue, whereas, leptin inhibits insulin secretion 
and insulin gene expression. The suppressive action of leptin on insulin production is regulated 
both by the autonomic nervous system and directly by influence on leptin receptors in B cells in 
pancreas. 
1.4. Leptin and the sympathetic (SNS) nervous system 
The interrelationship between leptin and the SNS is very strong. Leptin stimulates the  SNS,  
seen by increased  blood pressure (BP), thermogenesis (Scarpace, Matheny, Pollock, & Tumer, 
1997),  and increased NE turnover (Collins et al., 1996). Leptin infusion also  increases renal 
sympathetic nerve activity (SNA) by increasing sympathetic outflow to the kidney  (Haynes, 
Morgan, Walsh, Mark, & Sivitz, 1997). The sympathetic stimulatory effects were absent in 
Zucker rats (fa/fa) that have mutations in leptin receptors  (Haynes et al., 1997). Likewise in 
ob/ob mice, leptin produced no increase in NE turnover in WAT, an effect produced by leptin 
resistance. The proposed scenario is that leptin which is released from adipose tissue activates 
the SNS (Haynes et al., 1997) with inhibition of leptin secretion by SNS activation as a feedback 
mechanism (Hardie, Rayner, Holmes, & Trayhurn, 1996; Ricci, Fried, & Mittleman, 2000). 
Experimental studies in rats and mice showed increase in leptin mRNA and in plasma leptin after 
blockade of NE synthesis (Rayner & Trayhurn, 2001; Sivitz et al., 1999).  Data indicate a role of 
SNS in leptin gene expression modulation through a feedback loop to adipose tissue. 
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1.5. Sympathetic neural innervation of white adipose tissue 
One of the first studies to show direct WAT innervation by the  SNS (postganglionic SNS fibers) 
was performed in hamsters (Youngstrom & Bartness, 1995). Using histofluorescence, 
catecholaminergic fibers could easily be visualized in WAT (Rebuffe-Scrive, 1991; Slavin & 
Ballard, 1978).  Immunostaining for tyrosine hydroxylase (TH), a specific marker of sympathetic 
noradrenergic nerves, (Wilson et al., 1988) (Flatmark, 2000) also provided evidence for 
adrenergic innervation of WAT.  The pathway for innervation was documented using  
pseudorabies virus for track tracing (Bamshad, Aoki, Adkison, Warren, & Bartness, 1998).   SNS 
outflow from the brain to different depots of WAT is well documented (Bamshad et al., 1998; 
Bowers et al., 2004). After injection of pseudorabies (a transport marker) in WAT, there was 
widespread labeling in brainstem regions which control food intake and contain leptin receptors 
(Mercer, Moar, & Hoggard, 1998). In the hypothalamus, there was viral infection in the 
paraventricular nucleus (PVN), a region involved in sympathetic responses including blood 
pressure elevation and induction of lipolysis (Bartness & Bamshad, 1998). There was little 
labeling in the ventromedial hypothalamus even though this region is also involved in 
sympathetic responses and appetite control. TG storage is known as lipogenesis while secretion 
is known as lipolysis. High levels of lipogenesis cause obesity which is associated with 
hypertension, insulin resistance, and inflammation (Gustafson et al., 2009). WAT is heavily 
innervated by sympathetic fibers emanating from the CNS. The sympathetic terminals are 
involved in the control of fat secretion via activation of β-adrenergic receptors. In addition to 
adrenergic input, pancreatic insulin has prominent actions in WAT including inhibition of 
lipolysis (Chakrabarti & Kandror, 2011).  
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1.6. Energy balance in white adipose tissue 
The  action of the SNS in WAT is mediated by  β-adrenoceptors (β-AR)  and α2-adrenoceptors 
(α2-AR) (Lafontan et al., 1995). Catecholamines, NE and EPI, are released from the adrenal 
medulla or sympathetic nerve terminals and stimulate lipolysis by activating β receptors (Chu, 
Huddleston, Clancy, Harris, & Bartness, 2010; Carpene, Bousquet-Melou, Galitzky, Berlan, & 
Lafontan, 1998; Nonogaki, 2000; Bartness & Bamshad, 1998). Catecholamines also exert 
antilipolytic effects through stimulation of α2-AR. EPI and NE have a higher affinity for α2-AR 
than for β-AR indicating a role for the α2 adrenergic pathway in the control of lipolysis (Chen et 
al., 1996). If the activation of β-AR in WAT is stronger than the α-AR, then lipolysis is 
activated. If α-AR predominate, then lipolysis is inhibited (Bartness & Bamshad, 1998). Insulin 
has an inhibitory effect on lipolysis by reducing the number of adrenergic binding sites available 
by translocation of insulin receptors to the intracellular compartments. This causes a 
desensitization of ARs to catecholamine-stimulated lipolysis (Engfeldt, Hellmer, Wahrenberg, & 
Arner, 1988).  
1.7. Pathophysiological effects of fructose 
Fructose is found naturally in a variety of foods, such as fruits, honey, and vegetables. Fructose 
has a chemical formula C H O  similar to glucose. In glucose, an aldehyde group is attached 
at carbon 1, while in fructose the keto group is attached to carbon 2. The specificity and time 
course of fructose metabolism in the liver is related to the high maximum velocity of an enzymatic 
reaction  (Vm) and low dissociation constant of the enzyme-substrate complex (Km) of fructokinase 
(Heinz, Lamprecht, & Kirsch, 1968; Adelman, Ballard, & Weinhouse, 1967). In contrast to 
glucose, hepatic metabolism of fructose is not regulated by insulin.  In the first step of fructose 
metabolism in the liver, phosphorylation of fructose to fructose -1 phosphate occurs rapidly by 
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the action of fructokinase enzyme. This step occurs independently of insulin and without ATP 
feedback (Bruynseels et al., 1999; Cortez-Pinto et al., 1999). The rapid phosphorylation of 
fructose in the liver produces substrates for gluconeogenesis and lipogenesis.  
 The dramatic increase in fructose consumption in the last decades is thought to bear a 
relationship with the increased incidence of metabolic syndrome. In 2007, fructose intake in 
adults averaged almost 65 gm/day, mainly in the form of high fructose corn syrup (HFCS) 
(Tappy & Le, 2010). This global increase in fructose consumption is correlated with increased 
prevalence of metabolic syndrome, and type 2 diabetes mellitus (Montonen, Jarvinen, Knekt, 
Heliovaara, & Reunanen, 2007; Palmer et al., 2008), and obesity (Lustig, 2006; Isganaitis & 
Lustig, 2005). These syndromes are also associated with hypertension and cardiovascular disease 
(Dhingra et al., 2007; Fung et al., 2009).  
1.8. Effect of fructose on the sympathetic nervous system 
The activating effect  of dietary carbohydrates on SNS activity was originally documented more 
than 25 years ago (Young & Landsberg, 1977).  Results showed that high fructose consumption 
produces hypertension and insulin resistance in rodents (Dai & McNeill, 1995). One of the 
possible mechanisms was via increases in sympathetic neural outflow which increases plasma 
insulin and blood pressure (Hwang, Ho, Hoffman, & Reaven, 1987; Reaven, 1993). It was 
demonstrated in humans that fructose infusion amplified the release of EPI (Gabriely, Hawkins, 
Vilcu, Rossetti, & Shamoon, 2002). The ingestion of fructose  in rats increased plasma and 
urinary NE  (Jansen, Penterman, van Lier, & Hoefnagels, 1987) and increased adrenergic 
receptor expression in the heart (Kamide et al., 2002). Moreover, fructose feeding in mice 
produced nocturnal hypertension, sympathetic activation, and CNS catecholaminergic changes 
(Farah et al., 2006).  
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1.9. Circadian rhythms and fructose consumption   
Circadian rhythms should also be considered in the etiology of metabolic and cardiovascular 
pathologies associated with diabetes. Organisms adapt to their changing environment through 
tapping into a central clock, i.e., the suprachiasmatic nucleus (SCN). There are also independent 
peripheral clocks located in organs such as the liver and fat. Moreover, alterations in the pattern 
of eating, activity and sleeping may play a role in the development of metabolic syndrome (body 
weight, blood pressure, and insulin resistance). In humans, this is seen in pathologies associated 
with shift work, such as diabetes, weight gain, hypertension, coronary artery disease and other 
maladies (Morikawa et al., 2005; Esquirol et al., 2009). Even a short term alteration in day/night 
rhythms, such as from jet lag, was sufficient to produce an increase in blood pressure as well as 
metabolic derangements (Scheer, Hilton, Mantzoros, & Shea, 2009). In animals or humans, 
alteration of the feeding schedule resulted in significant changes in metabolic and endocrine 
parameters (Arble, Bass, Laposky, Vitaterna, & Turek, 2009; Kudo et al., 2004; Bodosi et al., 
2004; Zvonic et al., 2006; Colles, Dixon, & O'Brien, 2007). People with “night time eating” 
syndrome have a total caloric intake which is not different from healthy subjects. However, 
people with this syndrome gain more weight and have depression (Allison et al., 2005; Colles et 
al., 2007). Experimentally, feeding a group of mice a high fat diet in the inactive time (light 
period) also gave similar results, that is, greater weight gain without differences in caloric intake 
or activity (Arble et al., 2009). Similarly, changing the light cycle by exposing the animal to low 
light during the dark time, resulted in a syndrome of obesity and insulin resistance (Fonken et al., 
2010). When animals were forced to eat during the light, leptin levels were also increased 
(Bodosi et al., 2004). 
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1.10. Summary  
Alterations in the pattern of eating, activity, and sleeping may play a role in the development of 
the metabolic syndrome (increased body weight, blood pressure, and development of insulin 
resistance). In humans, this is seen in pathologies associated with shift work, such as, diabetes, 
obesity, hypertension, and coronary artery disease. Moreover, reversal of day/night cycles has 
effects on organs such as adipose tissue through the production of leptin and adiponectin. In 
addition to the function of adipose tissue as a reservoir for fat and an energy source, it is 
considered to be the body’s largest endocrine organ. In view of previous experiments which 
demonstrated that the day/night pattern of intake of sugar influences the development of 
metabolic pathologies, a protocol was designed in which the risk of both was combined. It was 
hypothesized that fructose provided in the light sleeping period in mice would exacerbate the 
sympathetic neural and metabolic responses. Consumption of fructose may result in obesity, 
diabetes, and autonomic dysfunction.  Recently, studies have shown that the consumption of 
fructose enhances the diabetic state by causing elevation in insulin levels. The rise in obesity 
with fructose consumption may occur because of its role in the lipogenic process.  Increasing 
adiposity and metabolic disturbances are also seen following alterations in day/night feeding 
schedule.  The aim of this study combined the effect of fructose and alteration of day time to test 
whether light-limited access to fructose alters metabolic function and adipose tissue 
catecholaminergic activity in mice. 
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2.  HYPOTHESIS AND SPECIFIC AIMS 
2.1. Hypothesis 
The timing of the access to dietary fructose intake will influence the metabolic and 
catecholaminergic response to fructose consumption. The hypothesis predicts that fructose given 
in light period in mice will increase catecholamine use in adipose tissue and catecholaminergic 
activity in the brainstem. In addition, it is predicted that limiting the time access of fructose to 
the light period will increase adiposity and influence metabolic parameters. 
2.2. Specific aims  
 
The specific aims of this study are: 
 
1. To test the hypothesis that timing (light vs. dark) of fructose consumption will 
influence body weight, body fat, fat cell size, and metabolic parameters. 
2. To test the hypothesis that timing (light vs. dark) of fructose consumption will 
influence catecholaminergic activity in adipose tissue and brainstem. 
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3. MATERIALS AND METHODS 
3.1. Animals 
C57BL/6 male mice with initial body weights (BW) of 22-24 g (Harlan Inc., Indianapolis, IN), 
were housed individually (22ºC) with 12 hr light (270 Lux) and 12 hr dark. Mice were given ad 
libitum access to standard mouse chow (58% CHO, 30% PRO, 12% FAT) and timed access to 
water or fructose (10% in tap water).  
3.2. Animals and treatments: 
C57BL/6 male mice were assigned randomly to groups:  1) Control: 24 hr water (n=10); 2) 
Fructose Light (FL): 12 hr fructose during the light period and 12 hr water during the dark period 
(n=11); and 3) Fructose  Dark (FD): 12 hr fructose solution during the dark period and 12 hr 
water during the light period (n=11).  Total fluid intake, chow consumed, body weight, and body 
fat was measured at weeks 2, 4 and 6. A glucose tolerance test was performed at week 8. Mice 
were sacrificed by decapitation at week 9. Experimental protocols were approved by the Wright 
State University Laboratory Animal Care and Use Committee. 
3.3. Histology and cell Measurement of white adipose tissue 
Epididymal adipose tissue was fixed in 4% paraformaldehyde.  Paraffin embedded tissues were 
sectioned (5 um) and stained with hematoxylin and eosin (H&E) (AML Laboratories Inc., 
Rosedale, MD). Tissues were examined using light microscopy and digital images were taken.  
Images were analyzed using a computerized imaging system, MetaMorph® version 7.6 
(Molecular Devices Inc., Sunnydale, CA).  Images were saved as 24-bit TIF files for computer 
processing.  Specifically, four tissue sections from each animal were used for analysis with two 
digital images made of each section.  For each image, the number and area of the cells were 
measured in a defined region.  The tissue was manually checked so that broken cells or damaged 
areas were removed from consideration. 
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3.4.  Immunohistochemical staining for tyrosine hydroxylase (TH) in epididymal fat 
To determine the level of tyrosine hydroxylase in fat tissue, fixed sections of epididymal fat were 
deparaffinized with xylene and hydrated. Sections were incubated in Na citrate (0.01M), boiled 
at 950C for 20 min, and cooled for one hour at room temperature.  Sections were then washed 
four times for 5 min each with 0.1 M. phosphate buffered saline (PBS) and washed with 0.5%  
bovine serum albumin (BSA, Sigma Aldrich, St. Louis, MO) plus 0.4% Triton X-100 (Fisher 
Scientific, Pittsburgh, PA) and 0.3% H2O2 (Sigma) for 15 min at room temperature to block 
endogenous peroxidase .  Tissue was then washed with PBS (7.5 pH) four times for 5 min and 
finally washed with 0.5% BSA for 10 min.  A hydrophobic pen was used to draw a circle around 
the tissue and allowed to dry before adding the blocking solution (normal goat serum in buffer 
1% BSA).  After incubating with primary TH antirabbit antibody  (Pel-Freeze Biologicals, 
Rogers, AR)  [1:500] for 1 hr at room temperature, the tissue was refrigerated overnight.  
After 24 hours incubation, the tissue was washed with 0.1M PBS (7.4 pH) four times for 
5 min each and then washed with 0.5% BSA for 10 min.  A secondary antibody (goat/antirabbit) 
was added [1:500] to the tissue and incubated for two hours at room temperature.  During this 
two-hour incubation period, ABC solution (Vector Laboratories, Burlingame, CA) was prepared 
at least 30 min prior to use.  Again, the tissue was washed with 0.01M PBS (7.4 pH) four times 
for 5 min each.  
The next step involved tissue washing with 0.5% BSA + 0.4% Triton -X100 in 0.01M 
PBS (7.4 pH) for 10 min. Following this, 1 ml of 0.01 M PBS + 2 µl of reagent A + 2 µl of 
reagent B were combined and allowed to sit on ice for 30 min.  This solution was then added to 
the slides, which sat for 1 hour at room temperature. The tissue was washed with 50 mM buffer 
A (8.505 g NaCl + 0.3405 g Midazol dissolved in 500 ml dH2O) two times for 5 min each, 
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washed with diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA) solution (40 ml 
buffer A + 10 mg tablet DAB 3 + 3, 3'-diaminobenzidine tetrahydrochloride + 200 µl of H2O2 + 
10 µl of 30% H2O2 + 1 ml  dH2O) and placed on a shaker for 10 min or until the tissue took on a 
brown color.  Slides were again rinsed with 0.01M PBS two times for 3 min each. Finally, the 
slides were dipped in H&E for 5 sec and dehydrated by going through increasing concentrations 
of ethanol (70%, 95%, and 100%) for 1 min each, ending in a 5 min xylene wash.  Cover slips 
were placed over the tissue using mounting media (Fisher Scientific, Pittsburgh, PA) and dried.  
Slides were photographed at 20X magnification. 
3.5. Immunohistochemistry of TH in brainstem 
The method was the same for TH staining in brainstem. Frozen (-800 C) brainstem sections (25 
um) from each group were processed for immunochemistry. The brainstem sections were rinsed 
in 0.01 M PBS (7.4 pH) solution. Slides were placed on a tray and allowed to sit at room 
temperature for one hour.  This step was followed by washing with 0.01 M PBS (7.4 pH) two 
times for 2 min each. The slides were next inserted into a container with 15% H2O2 ((2 µl of 
H2O2 + 10 ml of 0.1 M PBS (7.4 pH)) and placed on a shaker for 15 min.  After 15 min, the 
tissue was washed with 0.01 M PBS (7.4 pH) three times for 5 min each .A hydrophobic pen was 
used to draw a circle around the tissue and allowed to dry for few seconds before adding 
the blocking solution ((10 ml 0.01 M PBS (7.4 pH) + 150 ul of normal goat serum + 10 µl of 
0.4% Trion-100)). Primary antibody (Pel-Freeze Biologicals, Rogers, AR) rabbit/antirabbit 
[1:1000] was added. The tissue then sat at room temperature for one hour followed by 
refrigeration overnight. 
The next day slides were again washed with 0.1M PBS (7.4 pH) two times for 5 min 
each. Again, the tissues on slides were circled with a hydrophobic pen.  The secondary antibody, 
12 
goat/antirabbit (Vector Laboratories, Burlingame, CA), was added [1:1000] to the tissue and 
incubated for one hour.  While the tissue was incubating, an avidin-biotin peroxidase complex 
((2 µl of reagent A + 2 µl of reagent B + 1 ml of 0.01 M PBS (7.4 pH)) was prepared at least 30 
min prior to use and kept on ice.  After incubation, tissues were washed with buffer B.  This step 
was followed by washing the tissue with 50 mM of buffer A two times for 5 min each and lastly 
washed with DAB solution ((20 ml buffer B + 10 mg tablet DAB + 200 ul of H2O2 +10 µl of  
30% H2O2 + 1 ml dH2O)).  Containers with the slides were then set on the shaker with the DAB 
solution for 10 min (or until the tissue turned black).  
Tissues were rinsed to remove the DAB solution with 0.01 M PBS two times for 5 min 
each. Slides were then dried for 30 min to 1 hour and dehydrated using increasing percentages of 
ethanol 70%, 95%, 100% solutions for 1 min each.  Slides were then placed in xylene for 5 min. 
Cover slips were placed on the slide with mounting media (Fisher Scientific, Pittsburgh, PA) and 
dried.  Slides were photographed at 20X magnification. The TH was measured quantitatively by 
comparing one slide per animal from each group. 
3.5. High-performance liquid chromatography coupled with electrochemical detection 
(HPLC-ED) 
To determine the concentrations of norepinephrine (NE),  epinephrine (EPI), and  dopamine 
(DA) in fat, 60 mg of epididymal tissue was removed from the -800 C freezer and placed in a 
tube with  500 µl of cold 0.4 N perchloric acid and homogenized using a  sonicator three time at 
20 sec each.  Samples were then centrifuged at 4⁰ C and 13,000 rpm for 10 min.  Supernatant 
(400 µl) was transferred to a 2 ml tube.  To this tube, 50 mg of alumina (aluminium oxide) 
(Sigma-Aldrich, St. Louis, MO) and 45 µl of  dihydroxybenzylamine  hydrobromide (DHBA - 50 
ng/ml) were added.  DHBA was used as the internal standard and 0.5 M Tris buffer (9.0 pH) was 
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added to adjust the pH to 8.5.  The mixture was vortexed for 30 sec and centrifuged for 1 min at 
1000 rpm so that the alumina precipitated to the bottom. 
 After removing the buffer, the remaining alumina was washed with 1 ml of dH2O, 
vortexed, and centrifuged three times.  Elution was performed by adding 200 µl of 0.1 N 
perchloric acid (0.1 N perchloric acid with 1.0 mM Na metabisulfate).  Following a 30 sec vortex  
and spin for 1 min, the acid was removed.  The remaining homogenates were centrifuged at 
13,000 rpm at 40C for 10 min.  Two aliquots (20 µl) of supernatant were injected into the  HPLC. 
Chromatographic separation was conducted using an ESA 80 × 4.6 mm column packed with 3 
μm of C18 resin and a LC-4B amperometric detector (Bioanalytical Systems Inc. BASi) 
optimized to 0.75 V.   The mobile phase consisted of a stock of 8.204 sodium citrate, 0.0584 g 
EDTA disodium salt (C10H14O8Na2N2), 11.516 g citric acid, and 110 ml ProClin® solution. For 
running urinary catecholamines, 500 ml of stock solution + 0.12884 g 1-octanesulfonic acid 
(C8H17O3SNa: sodium ethyl hexyl sulfonate) and 35 ml MeOH (methanol) was made. The pH 
was adjusted to 8.5 using Tris buffer (9.0 pH).  The HPLC flow rate was set at 0.6 ml/min. A 
standard, containing a known amount of the monoamines - norepinephrine (NE), epinephrine 
(EPI), dihydroxybenzylamine hydrobromide (DHBA), and dopamine (DA), was injected into the 
chromatography system. The concentrations of monoamines in the samples were determined by 
comparing the peak amplitude from the samples to that obtained from known standard 
concentrations. The concentrations of NE, EPI, and DA were determined and expressed as pg/ng 
of tissue.  
3.6. Statistical analysis 
 
Male C57BL mice were given standard chow and assigned to one of three groups: Control 
(n=10, water 24h); FL (n=11, 10% fructose solution during 12h light period); and FD (n=10, 
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10% fructose solution during 12h dark period).  Statistical analysis was performed using 
GraphPad Prism® (v. 5.01) (GraphPad Software, La Jolla, CA) and STATISTICA® software 
(v.10) (StatSoft, Tulsa, OK). All data are expressed as mean ± SEM. Statistical significance was 
assessed by one-way, two-way, or repeated-measures analysis of variance (ANOVA) followed 
by Tukey’s HSD post hoc test.  The significance level was set at two-tailed p<0.05. 
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4. RESULTS 
4.1. Metabolic parameters 
4.1.1 Change in body weight: BW increased significantly for FL group  over the 6 wk time 
course (Fig 2).There was a significant difference in BW (p<0.05) observed for FL  as compared 
to FD. 
4.1.2 Change in body fat: There was a significant increase in BF in FL group (Fig 2) (2.6 and 1.5 
fold higher than Control and FD, respectively). FL animals had significantly more body fat 
(FL>FD>C, p<0.05). 
4.1.3 Adipocyte size: Fructose consumption induced a change in adipose cell size (Group effect, 
p<0.03) (Fig 3). Adipocytes were significantly larger in the FL group when compared to Control 
(p<0.05). 
4.1.5. Plasma insulin: At the experiment’s 8-week termination, insulin was measured in non-
fasted mice in the morning (Figure 4).  Mice fed fructose during the light period (FL) had 
significantly higher insulin levels compared to mice fed fructose during the dark (FD, p<0.05). 
There was no difference as compared to controls (Fig 4). 
4.1.6. Plasma leptin: There was a significant elevation in plasma leptin for mice fed fructose in 
the light period (FL) compared to those fed fructose during the dark period and controls. (Fig.4, 
p<0.05) . 
4.1.7 Glucose tolerance test GTT:  There was no significant difference among treatment groups 
for GTT data (FL: 192 ± 7.4 AUC/min, FD: 187 ± 7.5 AUC/min, Control: 204 ± 8.6 AUC/min)  
(Table 1). 
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4.1.8  Plasma glucose:  There was no significant difference in plasma glucose level among the 
groups, although there was significant increasing plasma levels of insulin and leptin hormones 
(FL: 139 ± 22.0 mg/dL, FD: 154.4 ± 21 mg/dL, Control: 157 ± 23.6 mg/dL) (Table 1). 
4.1.9 Plasma triglyceride and cholesterol levels: After 8 weeks, cholesterol and triglyceride 
levels of the fructose fed mice and the control group were measured using specific colorimetric 
assays. There was no significant difference among groups for these variables: cholesterol (FL 
92.6 ± 8.0 mg/dL, FD: 90 ± 5.5 mg/dL, Control: 82.7 ± 6.3 mg/dL); triglycerides (FL: 89 ± 12.0 
mg/dL, FD: 89 ± 8.0 mg/dL, Control: 82.7 ± 6.3 mg/dL) (Table 1). 
4.2. Measurement of Catecholamine Activity 
4.2.1 Immunohistochemistry of TH in white adipose tissue: Immunohistochemistry was 
conducted and followed by HPLC analyses, which quantitatively measured the catecholamine 
level. Immunostaining of TH for FL on adipose tissue and brainstem was used since it was 
difficult to measure catecholaminergic activity accurately using TH staining. Electrochemical 
methods for direct measurement of NE and EPI levels (Fig 6) were employed. 
4.2.2 Catecholamine level in white adipose tissue: To investigate the effect of fructose limited 
access time on catecholamine activity, HPLC method was performed to measure NE and EPI 
quantitatively in epididymal adipose tissue. There was a trend for higher levels of catecholamine 
in the FL group, which indicated that the time of response is critical (Fig 8). 
4.2.3 Immunohistochemistry of TH in brainstem: There was robust staining for TH in the 
brainstem, specifically in the locus coeruleus (LC). Staining was qualitatively greater in the FL 
group (Fig 9). 
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Table 1. Results of the glucose tolerance test (GTT) and plasma levels of glucose, adiponectin,    
triglycerides and cholesterol (after 8 weeks) 
 
Group GTT 
(AUC/min) 
Glucose 
(mg/dL) 
Adiponectin 
(µg/dL) 
Triglycerides 
(mg/dL) 
Cholesterol 
(mg/dL) 
      
Control 204±8.6 157.1±23.6 12. ±0 1.8       77± 9.3 82.7± 6.3 
F12L 192± 7.4 139 ±22.0 10.7± 2.4 89± 12.0 92.6± 8.0 
F12D 187 ±7.5 154.5± 21.0 11.5± 2.1 92.6± 8.0 90.2± 5.5 
Data are means ± SEM. There were no significant differences among the groups for any of the 
variables at 8 weeks. Control (n=10, water 24h); FL (n=11, 10% fructose solution during 12h 
light period); and FD (n=10, 10% fructose solution during 12h dark period). 
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Figure 2. Data are means ± SEM. Changes in (A) bodyweight and (B) body fat at 2 (    ) and 6 
weeks (   ) after the initiation of dietary treatment. Control (n=10, water 24h); FL (n=11, 10% 
fructose solution during 12h light period); and FD (n=10, 10% fructose solution during 12h dark 
period).Two-way repeated measures ANOVA showed a significant effect of time on bodyweight 
(F1,29 = 47.2; p< 0.0001). Two-way repeated measures ANOVA for body fat showed significant 
effects of Group (F2,29 = 3.85; p < 0.03), Time [(F1,29 = 60.6; p < 0.001) and a Group × Time 
interaction (F2,29 = 5.04; p< 0.013). **p< 0.01 compared with 2 weeks; †p< 0.01 compared with 
control values at 6 weeks; ‡ p< 0.05 compared with fructose dark group at 6 weeks. 
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Figure 3. Procedure for MetaMorph® for white adipose tissue (WAT). Images of WAT were 
processed to measure the adipocyte size on the mice in the three groups Control: water only; FL: 
water during dark period and fructose during light period; FD: water during light period and 
fructose during dark period. A and D are original images of WAT. B, E, C, and F are images of 
result of adipocyte size in certain region was created (800pixelx800 pixel) , For each image, the 
number and area of the cells were measured in a defined region. 
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Figure 4. Data are means ± SEM. Cell size in white epididymal fat. Fixed, hematoxylin and 
eosin stained tissue was examined using light microscopy and image analysis. Control (n=10, 
water 24h); FL (n=11, 10% fructose solution during 12h light period); and FD (n=10, 10% 
fructose solution during 12h dark period). Analysis using ANOVA showed a group effect (F2,18 = 
3.80; p< 0.042). *p< 0.05 compared with Control. 
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 Figure 5. Data are means ± SEM.  Insulin and leptin levels in the Control (n=10, water 24h); FL 
(n=11, 10% fructose solution during 12h light period); and FD (n=10, 10% fructose solution 
during 12h dark period). Analysis using ANOVA showed a significant Group effect for insulin 
(F2,17 = 5.62; p< 0.015) and leptin (F2,18 =3.85; p< 0.042). *p< 0.05 compared with the FD group. 
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Figure 6. Immunostaining of tyrosine hydroxylase (TH) in the white adipose tissue. TH staining 
showed localization of the brown reaction product in the adipose cells. A) Control: Water only; 
(B) FL: Water during dark period and fructose during light period; and (C) FD: Water during 
light period and fructose during dark period 
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Figure 7. Standards chart for catecholamine measuring (1nA). A standard, containing a known 
amount of the monoamines - norepinephrine (NE), epinephrine (EPI), dihydroxybenzylamine 
hydrobromide (DHBA), and dopamine (DA), was injected into the chromatography system. The 
concentrations of monoamines in the samples were determined by comparing the peak amplitude 
from the samples to that obtained from known standard concentrations. The concentrations of 
NE, EPI, and DA were determined and expressed as pg/ng of tissue.  
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Figure 8. Data are means ± SEM.  Plasma hormone levels (ng/mL). One-way ANOVA showed 
that there were no significant differences among the groups for catecholamine levels of NE and 
EPI.  Control (n=10, water 24h); FL (n=11, 10% fructose solution during 12h light period); and 
FD (n=10, 10% fructose solution during 12h dark period). 
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Figure 9. Immunostaining of tyrosine hydroxylase (TH) on brainstem of C57BL/6 mice in the 
locus coeruleus (LC). After 8 weeks of 10 % fructose treatment, staining was qualitatively 
greater in the FL group compared to FD and Control groups. Control (n=10, water 24h); FL 
(n=11, 10% fructose solution during 12h light period); and FD (n=10, 10% fructose solution 
during 12h dark period). 
 
 
 
 
 
 
 
 
 
26 
 
 
 
 
5. DISCUSSION 
 
This study tested the hypothesis that limited time access to fructose causes activation of adipose 
and brain catecholaminergic activity as well as metabolic pathologies in mice. The results show 
that consumption of fructose during the light or sleep period in male C57BL/6 mice produced 
altered metabolic and endocrine responses (Morris et al., 2011). This was seen as enhanced 
insulin and leptin levels with increased adiposity and fat cell size.  Immunohistochemistry 
showed staining for TH in adipose tissue and brainstem. Qualitative examination of the stain 
suggested increased catecholaminergic activity in both tissues. Electrochemical measurement of 
catecholamines, NE and EPI, in adipose tissue showed no significant changes. Our results 
document the importance of the timing of nutrient intake in causing metabolic disease. Questions 
remain as to the role of catecholamines in mediating the changes. 
 Epidemiological and experimental studies in humans and animals confirm that high 
fructose consumption causes metabolic and autonomic disorders including insulin resistance, 
obesity, autonomic dysfunction, and lipid and renal abnormalities (Bray, Nielsen, & Popkin, 
2004; Katovich et al., 2001; Dai & McNeill, 1995; Farah et al., 2006; Hsieh, 2005). Autonomic 
dysfunction plays a major role in the etiology of such syndromes. The clusters of metabolic and 
hemodynamic alterations are characterized by an increase in sympathetic drive (Grassi & 
Seravalle, 2006; Landsberg, 2001; De, Senador, Mostarda, Irigoyen, & Morris, 2012). There is 
much information on the cardiovascular and metabolic effects of a fructose supplemented diet in 
animal models. Fructose fed rats and mice show a moderate hypertension and glucose 
intolerance associated with high levels of plasma cholesterol, and TG (Lindmark, Wiklund, 
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Bjerle, & Eriksson, 2003; Kamide et al., 2002; Dai & McNeill, 1995; Farah et al., 2006; Hsieh, 
2005). There is evidence for a role of the sympathetic nervous and renin angiotensin systems 
(RAS) in fructose- induced cardiovascular and renal changes (Cunha et al., 2007; Van Gaal, 
Mertens, & De Block, 2006).  In a study done with fructose feeding in rats, fructose induced 
sympathetic activity and increased urinary catecholamine excretion (Kamide et al., 2002). An 
association between cardiovascular, autonomic and metabolic dysfunction in humans and 
animals has been demonstrated (Van Gaal et al., 2006; Hellstrom, 2007).    
As an index of catecholaminergic activity in adipose tissue, immunostaining for TH and 
electrochemistry for measurement of NE and EPI levels was utilized. Staining showed 
localization of the brown reaction product in the adipose cells. Given the structure of adipocytes 
which contain a large central vacuole (Fig 1), it was difficult to quantitatively compare staining 
in the tissues. This difficulty was also seen in the quantitative measurement of TH in vascular 
tissue. TH fibers were seen around vessels and in close association with adipocytes, but it was 
not possible to verify the level of change (Murano, Barbatelli, Giordano, & Cinti, 2009). In 
epididymal WAT of Siberian hamsters, it was also difficult to detect TH due to the close packing 
of the adipocytes (Shi, Song, Giordano, Cinti, & Bartness, 2005). However, in the present study 
it appeared that WAT staining was heavier in the FL group which had morefat and greater 
metabolic damage. In a quantitative assessment of TH activity in epididymal adipose tissue of 
fructose-fed rats, there were no significant differences between groups (Baret et al., 2002).  It 
was easier to detect nerve fibers in fat tissue from animals in a fasted state since cell size was 
smaller and parenchymal area was larger (Slavin & Ballard, 1978).  Because it was difficult to 
measure catecholaminergic activity accurately using TH staining, electrochemical methods for 
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direct measurement of NE and EPI levels were used (Lucot, Jackson, Bernatova, & Morris, 
2005). 
For the HPLC/electrochemical method, fat tissue is extracted with alumina, amines are 
separated by HPLC, and NE and EPI are measured by electrochemistry (Lucot, Crampton, 
Matson, & Gamache, 1989). This method is useful for measuring catecholamine levels 
accurately in tissues, urine, and plasma. NE levels in WAT were 0.08 pg/ng in FD vs. 16 pg/ng 
in FL. EPI levels were 0.14 pg/ng in FD vs. 9.45 pg/ng in FL (Fig. 8). The levels appear higher 
in the FL group as hypothesized, but because of the large variance, changes were nonsignificant. 
There are other reports of catecholamines in mice and rats WAT . Short term feeding (6 days) of 
fructose showed no change in NE levels in fat (Young, Weiss, & Boufath, 2004). Animals fed 
fructose for 6 weeks showed no significant change in SNS activation in epididymal (Baret et al., 
2002). Most experiments using fructose provide 24 hr accesses. The design of the present study 
is unique since it compares the effect of limited light/dark consumption. Indeed, there was a 
trend for increase both for TH and catecholamine content. 
As a complement to the adipose measurements, TH staining in the brainstem source for 
sympathetic innervation of adipose tissue was examined. There was robust staining for TH in the 
brainstem, specifically in the locus coeruleus (LC). Staining was qualitatively greater in the FL 
group (Fig. 10).  Similar results were seen when fructose was given in the food (Farah, Joaquim, 
& Morris, 2006; Farah et al., 2006). Fructose fed mice showed marked increases in brainstem 
TH mRNA expression, indicating central actions of the diet. CNS activation may play a role in 
the cardiovascular and metabolic changes induced by fructose.  
With regard to metabolic changes resulting from fructose consumption, body fat, fat cell 
size, and plasma levels of insulin and leptin were significantly increased. The changes were 
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specific for the FL group, verifying the important influence of timing (light/dark).   In a study 
performed in people who were fed three meals at different times over 24 hours (morning, 
afternoon, night), results showed that the group eating  at night had higher cholesterol levels than 
the morning and afternoon groups although these groups ate more food (Morikawa et al., 2007). 
High levels of TG were seen in shift workers, indicating that alteration of activity patterns is a 
risk factor for coronary disease (Knutsson, Akerstedt, & Jonsson, 1988). Moreover, individuals 
who worked at night showed higher risk for diabetes. Glycated hemoglobin was higher in night 
workers compared to those working on a fixed day time schedule (Morikawa et al., 2005). These 
studies established that alterations in sleeping or eating times are associated with risk factors 
related to type 2 diabetes and heart disease. Along with these results, studies also show increases 
in body weight in shift workers (obesity) (van Amelsvoort, Schouten, & Kok, 1999). 
Experimentally, increases in blood pressure and plasma insulin and glucose were also seen in 
individuals when circadian misalignment was induced, even acutely (Scheer et al., 2009). 
Similarly, in animals, such a misalignment (light-dark cycle reversed) influenced the induction of 
heart failure (Penev, Kolker, Zee, & Turek, 1998). Interestingly, heart attack and strokes were 
found to occur more often during the early waking hours in humans (Muller, 1999; Elliott, 1998). 
In mice exposed to chronic stress for 7 days, there were circadian patterns in the blood pressure 
responses, higher levels in the light vs. dark (Bernatova, Key, Lucot, & Morris, 2002). The 
experiments in the present study were designed to test the hypothesis that limited time access to 
fructose causes activation of adipose and brain catecholamine activity as well as metabolic 
pathologies. 
Unlike glucose, fructose metabolism is not regulated by the energy state. After fructose 
ingestion, its metabolism occurs independently of insulin because of the limitation of fructose 
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uptake by the pancreas that lacks GLUT5 fructose transporters (Curry, 1989). In the liver, 
fructose is rapidly phosphorylated by fructokinase and further converted to glyceraldehyde, 
dihydroxyacetone phosphate, and glyceraldehyde 3-phosphate, intermediates in the glycolytic 
pathway. These intermediates are metabolized to generate TG through the lipogenic process. The 
speed of the metabolism is due mainly to the high affinity of fructokinase for fructose and the 
phosphorylation which occurs independent of insulin. Therefore, fructose consumption has been 
suggested to increase hepatic TG which can be packed into very-low density lipoproteins by the 
liver and reduce TG clearance by adipose tissue. Although several studies linked fructose intake 
with elevation in TG and cholesterol (Dai & McNeill, 1995; Hsieh, 2005), in the present study 
there were no significant differences in TG or cholesterol among the treatment groups.  
Most studies provide continuous access to fructose.  The current study is unique since the 
access of fructose was coupled to a limited daily period (12 hr light vs. dark) demonstrating that 
there were significant differences among treatment groups depending on whether the sugar was 
given during the light or dark period. The FL group showed significant increases in adiposity and 
elevation in leptin and insulin levels. This occurred without differences in caloric intake among 
the groups. These results establish additional experimental evidence that the time of intake is 
critical to metabolism and the consequent pathologies. For example, when people are required to 
work at night, they demonstrate elevated TG, lower HDL cholesterol, and weight gain (Esquirol 
et al., 2009). People who work at night also have health implications in endocrine responses 
(Holmback et al., 2003). Alterations in the pattern of metabolic hormone secretion as well as 
increased body weight were confirmed in humans with nighttime snacking syndrome even 
though total food intake was not different from controls (Goel et al., 2009; Colles et al., 2007). 
Obesity and lack of blood glucose rhythms was noted in rats fed only during light time and 
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exposed to constant slow movement (Salgado-Delgado, Angeles-Castellanos, Saderi, Buijs, & 
Escobar, 2010). In the present study, fructose fed mice had an increase in fat cell size and body 
fat. There were metabolic changes, but no decrease in activity. Increased epididymal fat and cell 
size were noted in rats fed fructose (Furuhashi et al., 2004).   
The current data showed significant differences in metabolic response in mice fed 
fructose during the 12 hr light period. FL group had the highest levels of insulin and leptin 
plasma with enhanced adiposity. Leptin is mainly produced by adipose tissue. This hormone 
plays an important role in regulation of energy status by binding to specific receptors in the 
hypothalamus causing decreased food intake and increased energy expenditure (Havel, 2005). 
This organ is affected by alteration in circadian rhythms like other vital organs such as liver, 
heart and kidney (Damiola et al., 2000; Zvonic et al., 2006).   Additionally, leptin displays a 
diurnal pattern (Ahren, 2000; Teff et al., 2004) with other adipokines that are released from 
adipose tissue (Gavrila et al., 2003). Circulating leptin level is directly correlated to adiposity 
(Maffei et al., 1995). In addition, insulin and leptin have synergistic effects. Insulin increases 
leptin gene expression and has a role in the diurnal pattern of leptin secretion (Saad et al., 1998; 
Havel, 2002). 
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6. CONCLUSION 
 
 
 
The present study demonstrated that limited access time to a 10% fructose solution in mice 
increased adiposity and produced diabetic like symptoms. There was a trend for SNS activation 
as documented with TH staining (WAT and brainstem) and catecholamine levels in adipose 
tissue.  The changes were specific for the FL group and were dissociated from caloric intake. 
Changes occurred when mice were given the sugary liquid during the light (inactive) period as 
compared to dark phase consumption. Hormonal effects included increases in leptin and insulin 
without changes in glucose or glucose tolerance.  In conclusion, the results of the present study 
document that restricting fructose access to the light inactive period produced pathological 
effects as related to body fat, adipocyte size, and metabolic hormones with a trend toward SNS 
changes. These data may have clinical implications, since the timing of intake could be important 
in the control of adiposity and the development of metabolic syndrome. 
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